XRCC1 and glioma: Recently, meta-analysis studies have reported that XRCC1 Arg399Gln variant was associated with the risk of certain cancers, such as breast cancer [29], nasopharyngeal carcinoma [30], cervical carcinoma [31] and glioma [32].